Gara Jalqabaatti › Distrophii Qaraa
Qorannoo klinikaalii Distrophii Qaraa Ameerikaa Keessatti hirmaatuu
Qorannoo 27 Distrophii Qaraa f bakka adda addaa Ameerikaa Keessatti hirmaatuu jiru.
Magaalota qorannoo baay'ee qaban
- Washington, DCQorannoo 8
- Chicago, ILQorannoo 4
- Sacramento, CAQorannoo 4
- Boston, MAQorannoo 4
- Gainesville, FLQorannoo 3
- Little Rock, ARQorannoo 3
- Durham, NCQorannoo 3
- Mountain View, CAQorannoo 3
Naannoon
- ArkansasQorannoo 3
- CaliforniaQorannoo 6
- Distaarikii KoloombiyaaQorannoo 4
- FloridaQorannoo 3
- IllinoisQorannoo 4
- MarylandQorannoo 5
- MassachusettsQorannoo 4
- New YorkQorannoo 3
- North CarolinaQorannoo 4
- TexasQorannoo 4
Qorannoo yeroo dhihootti haaromfaman
Takkalaa qorannoo (Ingiliffa)
Study of Inherited Neurological Disorders
Namoota walitti qabaa jiraQorannoo ilaalaa
Umuriin 2 hanga 120 · Saalaa hunda · Haaromfame 28-Ful-2026 · NCT00004568Registry Study to Observe Long-term Safety of Vamorolone (AGAMREE®) in Patients With Duchenne Muscular Dystrophy-SUMMIT
Namoota walitti qabaa jiraQorannoo ilaalaa
Umuriin 2 fi ol · Dhiroota · Haaromfame 24-Ful-2026 · NCT06564974Investigational Use of Neuromuscular Ultrasound
Namoota walitti qabaa jiraQorannoo ilaalaaHojjettoota fayyaa simatamoo
Umuriin 18 hanga 110 · Saalaa hunda · Haaromfame 17-Ful-2026 · NCT05237973Establishing Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type 1 (END-DM1) Extension
Namoota walitti qabaa jiraQorannoo ilaalaa
Umuriin 18 hanga 70 · Saalaa hunda · Haaromfame 04-Ful-2026 · NCT07700225Interfacing With NeuroTechnology to Expand Neural Throughput (INTENT)
Namoota walitti qabaa jira
Umuriin 18 hanga 80 · Saalaa hunda · Haaromfame 02-Ful-2026 · NCT07521930Sodium/Glucose Cotransporter-2 Inhibitors (SGLT2i) Therapy in Duchenne Cardiomyopathy
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 8 hanga 18 · Dhiroota · Haaromfame 24-Hag-2026 · NCT07172971Evaluating VM100 Nutritional Supplement for Improving Quality of Life in Duchenne Muscular Dystrophy Patients
Namoota walitti qabaa jira
Umuriin 6 fi ol · Dhiroota · Haaromfame 17-Hag-2026 · NCT07766980Once Weekly Infant Corticosteroid Trial for DMD
Namoota walitti qabaa jiraSadarkaa 4
1 Month – 30 Months · Dhiroota · Haaromfame 14-Hag-2026 · NCT05412394Toward Ubiquitous Lower Limb Exoskeleton Use in Children and Young Adults
Namoota walitti qabaa jiraQorannoo ilaalaa
Umuriin 5 hanga 25 · Saalaa hunda · Haaromfame 23-Ado-2026 · NCT06998134A Study Evaluating the Real-World Experience of Givinostat in Patients With Duchenne Muscular Dystrophy
Namoota walitti qabaa jiraQorannoo ilaalaa
Umuriin 6 fi ol · Saalaa hunda · Haaromfame 02-Ado-2026 · NCT07127978PBGENE-DMD Phase 1/2a Safety and Preliminary Efficacy Study in Duchenne Muscular Dystrophy (FUNCTION-DMD)
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 2 hanga 7 · Dhiroota · Haaromfame 23-Wax-2026 · NCT07429240Feasibility of the BrainGate2 Neural Interface System in Persons With Tetraplegia
Namoota walitti qabaa jira
Umuriin 18 hanga 80 · Saalaa hunda · Haaromfame 02-Wax-2026 · NCT05724173BrainGate2: Feasibility Study of an Intracortical Neural Interface System for Persons With Tetraplegia
Namoota walitti qabaa jira
Umuriin 18 hanga 80 · Saalaa hunda · Haaromfame 01-Wax-2026 · NCT00912041Duchenne Electronic Health Record Study
Namoota walitti qabaa jiraQorannoo ilaalaa
Umuriin hundi · Saalaa hunda · Haaromfame 27-Cam-2026 · NCT07609394Efficacy, Safety, and Tolerability of Zeleciment Rostudirsen (DYNE-251) Administered Intravenously Every 4 Weeks in Ambulatory Participants With Duchenne Muscular Dystrophy (FORZETTO)
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 4 hanga 18 · Dhiroota · Haaromfame 27-Cam-2026 · NCT07608432Vasodilator and Exercise Study for DMD (VASO-REx)
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 6 fi ol · Dhiroota · Haaromfame 15-Cam-2026 · NCT06290713Nomad P-KAFO Study
Namoota walitti qabaa jira
Umuriin 18 hanga 89 · Saalaa hunda · Haaromfame 11-Cam-2026 · NCT05644522The Duchenne Registry
Namoota walitti qabaa jiraQorannoo ilaalaa
Umuriin hundi · Saalaa hunda · Haaromfame 08-Cam-2026 · NCT02069756ECoG BMI for Motor and Speech Control
Namoota walitti qabaa jira
Umuriin 21 fi ol · Saalaa hunda · Haaromfame 05-Cam-2026 · NCT03698149Muscle Health Measurements Using Electrical Impedance Myography
Namoota walitti qabaa jiraQorannoo ilaalaaHojjettoota fayyaa simatamoo
Umuriin 18 hanga 89 · Saalaa hunda · Haaromfame 03-Elb-2026 · NCT07502989Development of Quantitative Muscle Imaging as a Biomarker of Disease Endpoints in Myotonic Dystrophy
Namoota walitti qabaa jiraQorannoo ilaalaaHojjettoota fayyaa simatamoo
Umuriin 18 hanga 65 · Saalaa hunda · Haaromfame 23-Ama-2026 · NCT07362875Feasibility of the BrainGate2 Neural Interface System in Persons With Tetraplegia (BG-Speech-02)
Namoota walitti qabaa jira
Umuriin 18 hanga 80 · Saalaa hunda · Haaromfame 01-Mud-2025 · NCT06094205Long-Term Development of Muscular Dystrophy Outcome Assessments
Namoota walitti qabaa jiraQorannoo ilaalaa
Umuriin 6 hanga 50 · Saalaa hunda · Haaromfame 18-Sad-2025 · NCT05989620Evaluating Long-term Use of a Pediatric Robotic Exoskeleton (P.REX/Agilik) to Improve Gait in Children With Movement Disorders
Namoota walitti qabaa jira
Umuriin 3 hanga 17 · Saalaa hunda · Haaromfame 27-Onk-2025 · NCT05726591Myotonic Dystrophy and Facioscapulohumeral Muscular Dystrophy Registry
Namoota walitti qabaa jiraQorannoo ilaalaaHojjettoota fayyaa simatamoo
Umuriin hundi · Saalaa hunda · Haaromfame 15-Onk-2025 · NCT00082108Kanneen ClinicalTrials.gov irraa argaman, daataa 06-Onk-2026 irratti argame. Qorannoon hundi isaa kan ofii qajeelfama qoodfannaa qaba; gareen qorannoo eenyu akka hirmaatu murteessa.